ALEC
Closed
Alector Inc
1.42
+0.02 (+1.43%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.4
Day's Range: 1.34 - 1.51
Send
sign up or login to leave a comment!
When Written:
6.19
Alector Inc is a clinical stage biotechnology company that focuses on developing therapies for neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Alector's approach to developing therapies is based on the concept of immuno-neurology, which involves using the body's immune system to target and clear toxic proteins that are associated with neurodegenerative diseases such as Alzheimer's and Parkinson's.
The company's lead drug candidate, AL001, is being developed for the treatment of frontotemporal dementia, a rare and devastating form of dementia that affects the frontal and temporal lobes of the brain. Alector is also developing a pipeline of other drug candidates for the treatment of Alzheimer's, Parkinson's, and other neurodegenerative diseases.
Alector has partnerships with several pharmaceutical companies, including AbbVie, which is co-developing AL001, and GlaxoSmithKline, which is collaborating with Alector on the development of drugs for Parkinson's disease.
As of 2021, Alector had a market capitalization of approximately $1.4 billion and had raised over $700 million in funding from investors including Fidelity, Google Ventures, and Polaris Partners.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Alector's approach to developing therapies is based on the concept of immuno-neurology, which involves using the body's immune system to target and clear toxic proteins that are associated with neurodegenerative diseases such as Alzheimer's and Parkinson's.
The company's lead drug candidate, AL001, is being developed for the treatment of frontotemporal dementia, a rare and devastating form of dementia that affects the frontal and temporal lobes of the brain. Alector is also developing a pipeline of other drug candidates for the treatment of Alzheimer's, Parkinson's, and other neurodegenerative diseases.
Alector has partnerships with several pharmaceutical companies, including AbbVie, which is co-developing AL001, and GlaxoSmithKline, which is collaborating with Alector on the development of drugs for Parkinson's disease.
As of 2021, Alector had a market capitalization of approximately $1.4 billion and had raised over $700 million in funding from investors including Fidelity, Google Ventures, and Polaris Partners.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!